北京诺禾致源科技股份有限公司 | Novogene Co., Ltd.

Beijing Novogene Technology Co., Ltd. (Stock Code: 688315) was incorporated in March 2011 at the Zhongguancun Life Science Park in Beijing. The company is dedicated to advancing the application of cutting-edge molecular biology technologies and high-performance computing in life science research and human health, with the commitment to becoming a world-leading provider of gene technology products and services. Novogene has established a multi-omics service platform with industry-leading sequencing throughput, providing comprehensive services across genomics, transcriptomics, single-cell and spatial omics, proteomics, metabolomics, and integrated multi-omics research systems. In terms of third-generation sequencing, Novogene has introduced various single-molecule real-time sequencing platforms, including Oxford Nanopore (e.g., PromethION devices). The core advantages of third-generation sequencing lie in single-molecule sequencing without PCR amplification, featuring ultra-long read lengths, no GC bias, and direct reading of base modification information. Building on this foundation, third-generation sequencing enables T2T genome assembly, whole-genome sequencing, ultra-long-read DNA sequencing, metagenomics, methylation studies, transcriptomics, and direct RNA sequencing, yielding unbiased DNA and RNA information.